Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Irish MedTech company focused on remote monitoring of heart failure patients.
FIRE1 is a connected medical device solutions company dedicated to improving outcomes for people suffering from chronic diseases. Its first product is a novel remote monitoring solution for heart failure patients. FIRE1 is led by an experienced medical devices team who are working closely with researchers, clinicians, patients and payors to help reduce the burden of heart failure.
More Fire1 news
Gilde Healthcare company FIRE1 raises $25 million to revolutionize heart failure home monitoring
Gilde Healthcare leads EUR 40 Million financing in Irish healthtech company FIRE1
Venture&Growth
CVRx
US-based MedTech company focused on treatment of heart failure applying neurostimulation.

Venture&Growth
SynOx Therapeutics
SynOx Therapeutics Limited is a Dublin-based, late clinical-stage biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders. TGCT is a rare, non-malignant but

Venture&Growth
MicroTransponder
MicroTransponder is a U.S.-based, growth-stage company commercializing the Vivistim Paired VNS System, an implantable neurostimulation therapy that improves outcomes for chronic ischemic stroke survivors with upper limb motor deficits. Vivistim Paired VNS System is an implantable neurostimulation therapy that helps
